{"pub": "marketwatch", "url": "https://marketwatch.com/articles/myriad-stock-ceo-mark-capone-sold-51567614228", "downloaded_at": "2019-09-04 23:48:13.399515+00:00", "published_at": "2019-09-04", "title": "Myriad Executives Sold Stock Before Shares Plunged", "language": "en", "text": "Myriad Genetics stock dropped 50% last month, after an Aug. 13 conference call in which the genetic-testing company said that its key new product GeneSight was in hot water with U.S. Food and Drug Administration. Companies with similar products say they learned of the FDA concerns back in July.\n\nSo the question arises: When did Myriad (ticker: MYGN) first learn of the FDA problem that clobbered its stock? The question becomes more intriguing in light of some $10 million in stock sales that President and CEO Mark Capone and...", "description": "CEO Capone and other executives sold $10 million of shares on Aug. 1 through trading plans. Myriad Genetics stock dove after an Aug. 13 conference call in which the company said that its key new product GeneSight was in hot water with the FDA.", "authors": ["Bill Alpert"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DE894_Geneti_OR_20190904090148.jpg"}